Specifically, upregulated DLX6-AS1 in gastric cancer tissue associated with distant metastasis and a poor clinical prognosis, while siRNA-DLX6-AS1 may inhibit gastric cancer cell proliferation, migration, invasion and the epithelial–mesenchymal transition in vitro (18). Here, DLX6 is linked to gastric cancer.